Polyethylene Glycol 4000 for Fecal Disimpaction in Cerebral Palsy Children.
PEG4000
cerebral palsy
child health
constipation
fecal impaction
Journal
Iranian journal of child neurology
ISSN: 1735-4668
Titre abrégé: Iran J Child Neurol
Pays: Iran
ID NLM: 101463836
Informations de publication
Date de publication:
2024
2024
Historique:
received:
11
03
2022
accepted:
22
10
2022
pmc-release:
01
04
2024
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
20
2
2024
Statut:
ppublish
Résumé
This study evaluated the efficacy of Polyethylene glycol 4000 for fecal disimpaction in children with cerebral palsy. A randomized control trial study was conducted on children with cerebral palsy between February - March 2017 in the pediatric neurology outpatient clinic Dr. Soetomo Hospital. Children aged 2-16 years with fecal impaction randomly assigned into polyethylene glycol 4000 (PEG 4000) and saline enema group. Polyethylene glycol 4000 was given at a dosage of 0.7 g/kg and enema using normal saline 15ml/kg twelve hourly. Constipation was diagnosed using ROME IV criteria, and abdominal palpation identified fecal impaction. Efficacy was evaluated by clinical observation and adverse symptom monitoring. Data were analyzed by statistical software using an independent t-test (p<0,05). Thirty-two children were randomized into the study. Muscle relaxant was discovered in 17/32 patients. Sex, age, and body weight were not statistically different between groups. The resolution of fecal impaction was significantly different between PEG 4000 and saline enema (21.69 hours and 39 hours respectively; p=0.001). Application of muscle relaxant and severity of the disease did not involve treatment efficacy. There was no adverse symptom reported during treatment. Polyethylene glycol 4000 results in fecal disimpaction faster than enema in constipated children with cerebral palsy.
Identifiants
pubmed: 38375128
doi: 10.22037/IJCN.v17i2.37876
pmc: PMC10874514
doi:
Types de publication
Journal Article
Langues
eng
Pagination
61-69Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
None